Compare WEAV & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WEAV | ZVRA |
|---|---|---|
| Founded | 2011 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 487.7M | 472.9M |
| IPO Year | 2021 | 2015 |
| Metric | WEAV | ZVRA |
|---|---|---|
| Price | $4.88 | $9.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $11.00 | ★ $21.71 |
| AVG Volume (30 Days) | ★ 1.9M | 887.8K |
| Earning Date | 05-20-2026 | 06-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 7.50 | ★ 159.21 |
| EPS | N/A | ★ 1.35 |
| Revenue | ★ $239,024,000.00 | $106,470,000.00 |
| Revenue This Year | $17.20 | $333.64 |
| Revenue Next Year | $13.74 | $44.19 |
| P/E Ratio | ★ N/A | $7.54 |
| Revenue Growth | 16.99 | ★ 350.91 |
| 52 Week Low | $4.72 | $6.19 |
| 52 Week High | $12.19 | $13.16 |
| Indicator | WEAV | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 33.99 | 60.02 |
| Support Level | N/A | $8.32 |
| Resistance Level | $7.31 | $10.05 |
| Average True Range (ATR) | 0.29 | 0.46 |
| MACD | -0.00 | 0.14 |
| Stochastic Oscillator | 15.71 | 55.05 |
Weave Communications Inc is a customer experience and payments software platform tailored for SMB healthcare businesses, that revolutionizes patient interaction from initial contact to billing. It integrates diverse workflows into a unified solution, minimizing manual tasks and maximizing patient engagement. Weave democratizes enterprise-level communication tools, simplifying them for SMBs in a singular platform. Offering varied communication channels, appointment scheduling, payment processing, and more, enhances practitioner-patient relationships and optimizes practice operations. The company has a singular operating segment and revenue from subscription services.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.